Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Hodgkin Disease 7Multiple Myeloma 6Leukemia 6Neoplasm Metastasis 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Prostatic Neoplasms 4Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Graft vs Host Disease 4Blast Crisis 4Sarcoma 3Primary Myelofibrosis 3Pancreatic Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Large B-Cell, Diffuse 3Burkitt Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Sirolimus × Clear all
NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

National Cancer Institute (NCI)

Phase 2 Terminated
4 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡